Hospital
DLP Marquette General Hospital LLC
DLP Marquette General Hospital LLC was paid $16.29M by Medicaid between Jan 2018 and Dec 2024, across 292 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoDLP MARQUETTE GENERAL HOSPITAL LLC
MARQUETTE, MI 49855
MARQUETTE, MI 49855
33aNPI1568727048assigned 07/10/2012
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.29M
24GClaims656,132
24DCodes billed292
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#53 of 86
Median peer was paid$21.55M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 108,071 | $2.49M | |
| 2019 | 97,007 | $2.25M | |
| 2020 | 84,716 | $2.09M | |
| 2021 | 99,282 | $2.73M | |
| 2022 | 98,688 | $2.52M | |
| 2023 | 97,801 | $2.43M | |
| 2024incomplete | 70,567 | $1.79M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 13,481 | 12,428 | $2.64M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 6,365 | 5,906 | $2.22M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.9% | 11,757 | 10,870 | $1.44M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.9% | 26,888 | 7,828 | $962K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.4% | 11,624 | 10,696 | $725K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.9% | 9,126 | 8,169 | $641K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 9,079 | 8,572 | $408K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.0% | 9,091 | 4,787 | $331K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 2,051 | 1,975 | $309K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.9% | 7,376 | 2,281 | $302K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.8% | 915 | 899 | $298K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 4,192 | 3,997 | $289K |
280 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 1,169 | $270K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 2,705 | $252K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 895 | $225K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 5,980 | $214K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.3% | 1,028 | $204K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 2,192 | $190K |
| 80061 | Lipid panel | 1.2% | 10,413 | $189K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 6,553 | $183K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 1,696 | $164K |
| 97161 | <1% | 3,005 | $156K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 10,039 | $148K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,525 | $144K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 527 | $137K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,485 | $129K |
| 80053 | Comprehensive metabolic panel | <1% | 33,494 | $125K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,557 | $122K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,350 | $114K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,086 | $113K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 7,871 | $111K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,978 | $110K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,908 | $101K |
| 92523 | <1% | 780 | $88K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,140 | $78K |
| 36415 | Collection of venous blood by venipuncture | <1% | 40,250 | $77K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 403 | $72K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 598 | $69K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,641 | $68K |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,223 | $65K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 144 | $65K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,201 | $64K |
| 86900 | <1% | 2,386 | $57K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 945 | $54K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,753 | $53K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 2,462 | $48K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 459 | $47K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 88 | $44K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 382 | $42K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,941 | $42K |
| 72100 | <1% | 1,130 | $42K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 80 | $38K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,041 | $38K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,072 | $37K |
| 76830 | Ultrasound, transvaginal | <1% | 607 | $35K |
| 87480 | <1% | 3,225 | $29K | |
| 87510 | <1% | 3,223 | $29K | |
| 87660 | <1% | 3,225 | $29K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,135 | $27K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,331 | $26K |
| 97014 | <1% | 3,303 | $26K | |
| 85027 | <1% | 12,226 | $25K | |
| 86803 | <1% | 3,339 | $24K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,174 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 10,590 | $23K |
| 84439 | <1% | 5,485 | $23K | |
| 82728 | <1% | 3,270 | $22K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,746 | $22K |
| 82607 | <1% | 2,753 | $21K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,378 | $21K |
| 62323 | <1% | 61 | $20K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 155 | $20K |
| 96367 | <1% | 273 | $18K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,970 | $18K |
| 87088 | <1% | 5,825 | $18K | |
| 87522 | Neg quan hep c or qual rna | <1% | 756 | $18K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,013 | $17K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,854 | $17K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 204 | $16K |
| 87077 | <1% | 3,942 | $16K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 170 | $14K |
| 82746 | <1% | 1,925 | $14K | |
| 84481 | <1% | 1,766 | $14K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,866 | $14K |
| 64483 | <1% | 25 | $13K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 189 | $11K |
| 76536 | <1% | 205 | $11K | |
| 97162 | <1% | 213 | $11K | |
| 81513 | <1% | 163 | $11K | |
| 87340 | <1% | 2,188 | $11K | |
| 81001 | <1% | 14,861 | $11K | |
| 87186 | <1% | 2,937 | $11K | |
| 87653 | <1% | 584 | $10K | |
| 73562 | <1% | 520 | $10K | |
| 83970 | <1% | 491 | $10K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 194 | $10K |
| 97165 | <1% | 195 | $10K | |
| 86706 | <1% | 1,697 | $9K | |
| 86704 | <1% | 1,445 | $9K | |
| 88342 | <1% | 483 | $9K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 12 | $8K |
| 73630 | <1% | 771 | $8K | |
| 80081 | <1% | 200 | $8K | |
| 93225 | <1% | 234 | $8K | |
| 72040 | <1% | 162 | $8K | |
| 84403 | <1% | 590 | $8K | |
| 64493 | <1% | 18 | $8K | |
| 97166 | <1% | 143 | $8K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 30 | $8K |
| 87081 | <1% | 2,799 | $7K | |
| 83735 | <1% | 8,280 | $7K | |
| 82570 | <1% | 2,653 | $7K | |
| 87070 | <1% | 1,963 | $7K | |
| 76642 | <1% | 184 | $6K | |
| 86708 | <1% | 950 | $6K | |
| 82043 | <1% | 2,009 | $6K | |
| 86140 | <1% | 3,409 | $6K | |
| 86038 | <1% | 1,027 | $6K | |
| 74018 | <1% | 307 | $6K | |
| 86850 | <1% | 2,329 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 513 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 569 | $5K |
| 93017 | <1% | 263 | $5K | |
| 85610 | <1% | 5,308 | $5K | |
| 84466 | <1% | 758 | $5K | |
| 73130 | <1% | 526 | $5K | |
| 72141 | <1% | 41 | $5K | |
| 83540 | <1% | 1,408 | $5K | |
| 80076 | <1% | 3,232 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 121 | $4K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 325 | $4K |
| 73030 | <1% | 317 | $4K | |
| 73610 | <1% | 419 | $4K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,767 | $4K |
| 83880 | <1% | 628 | $4K | |
| 84702 | <1% | 797 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,311 | $4K |
| 82784 | <1% | 710 | $4K | |
| 87641 | <1% | 657 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 202 | $4K |
| 84480 | <1% | 473 | $3K | |
| 87640 | <1% | 657 | $3K | |
| 97035 | <1% | 589 | $3K | |
| 87807 | <1% | 1,236 | $3K | |
| 85652 | <1% | 2,826 | $3K | |
| 81025 | <1% | 6,628 | $3K | |
| 83690 | <1% | 5,210 | $3K | |
| 83516 | <1% | 416 | $3K | |
| 87902 | <1% | 31 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 162 | $3K |
| 87481 | <1% | 161 | $3K | |
| 73110 | <1% | 182 | $3K | |
| 86593 | <1% | 1,031 | $3K | |
| 73502 | <1% | 126 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 173 | $2K |
| 87205 | <1% | 1,452 | $2K | |
| 86376 | <1% | 277 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 70 | $2K |
| 97163 | <1% | 41 | $2K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 12 | $2K |
| 74178 | <1% | 12 | $2K | |
| 93307 | <1% | 14 | $2K | |
| 71271 | <1% | 27 | $2K | |
| 93971 | <1% | 27 | $2K | |
| 82565 | <1% | 1,062 | $2K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 13 | $2K |
| 87498 | <1% | 84 | $2K | |
| 76775 | <1% | 53 | $2K | |
| 0002A | <1% | 59 | $1K | |
| 83525 | <1% | 214 | $1K | |
| 85730 | <1% | 1,787 | $1K | |
| 86431 | <1% | 463 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 13 | $1K |
| 93296 | <1% | 83 | $1K | |
| 84484 | <1% | 4,772 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 86 | $942.32 |
| 97116 | <1% | 121 | $938.73 | |
| 82550 | <1% | 438 | $871.10 | |
| 74019 | <1% | 102 | $869.02 | |
| 84146 | <1% | 93 | $840.38 | |
| 86800 | <1% | 95 | $760.88 | |
| 84703 | <1% | 2,304 | $759.38 | |
| 87046 | <1% | 168 | $746.02 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 64 | $743.02 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 43 | $725.60 |
| 85379 | <1% | 1,494 | $694.11 | |
| 87493 | <1% | 50 | $623.16 | |
| 87427 | <1% | 136 | $603.88 | |
| 86592 | <1% | 239 | $595.16 | |
| 0001A | <1% | 39 | $586.06 | |
| 86787 | <1% | 94 | $565.31 | |
| 0012A | <1% | 23 | $507.87 | |
| 82962 | <1% | 4,577 | $491.85 | |
| 82670 | <1% | 36 | $491.54 | |
| 71250 | <1% | 13 | $458.40 | |
| 86200 | <1% | 75 | $410.13 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 15 | $407.82 |
| 82950 | <1% | 147 | $400.74 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $387.12 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $379.08 |
| 87045 | <1% | 84 | $373.01 | |
| 86141 | <1% | 65 | $361.92 | |
| 85007 | <1% | 421 | $357.76 | |
| 83001 | <1% | 38 | $354.89 | |
| 83605 | <1% | 1,591 | $338.36 | |
| 0011A | <1% | 19 | $303.05 | |
| 84156 | <1% | 176 | $282.40 | |
| 87040 | <1% | 995 | $281.26 | |
| 85651 | <1% | 172 | $273.78 | |
| 83655 | <1% | 40 | $273.38 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,831 | $266.33 |
| 88304 | <1% | 96 | $259.73 | |
| 84550 | <1% | 156 | $247.50 | |
| 84153 | <1% | 25 | $232.03 | |
| 87185 | <1% | 110 | $225.07 | |
| 83615 | <1% | 196 | $222.41 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 565 | $211.82 |
| 86618 | <1% | 24 | $210.90 | |
| 82150 | <1% | 69 | $208.30 | |
| 97033 | <1% | 21 | $167.85 | |
| 94690 | <1% | 12 | $162.80 | |
| 82310 | <1% | 66 | $135.41 | |
| 87015 | <1% | 151 | $126.93 | |
| 82274 | <1% | 13 | $120.00 | |
| 86780 | <1% | 12 | $94.56 | |
| 82947 | <1% | 38 | $94.22 | |
| 82105 | <1% | 12 | $92.84 | |
| 87177 | <1% | 14 | $61.49 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,459 | $55.44 |
| 82390 | <1% | 12 | $54.00 | |
| 80069 | <1% | 12 | $53.79 | |
| 86225 | <1% | 12 | $42.82 | |
| 82040 | <1% | 14 | $37.32 | |
| 93325 | <1% | 1,176 | $35.63 | |
| 86901 | <1% | 2,387 | $30.28 | |
| 86308 | <1% | 12 | $29.25 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,124 | $16.87 |
| 84100 | <1% | 14 | $14.27 | |
| 82077 | <1% | 122 | $9.45 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,149 | $5.49 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,383 | $2.14 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 717 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 697 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 9,044 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,220 | $0.00 |
| 93226 | 0% | 184 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 175 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 7,112 | $0.00 |
| 90715 | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 70 | $0.00 |
| J3250 | Injection, trimethobenzamide hcl, up to 200 mg | 0% | 60 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 295 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 12 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 189 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 31 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 14 | $0.00 |
| 76000 | 0% | 12 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 18 | $0.00 |
| 80179 | 0% | 13 | $0.00 | |
| 80143 | 0% | 13 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 13 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 14 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 21 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 1,779 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 1,564 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 7,898 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 2,537 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 288 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 7,265 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 714 | $0.00 |
| 96376 | 0% | 2,327 | $0.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,541 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 6,763 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 845 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 454 | $0.00 |
| C1769 | Guide wire | 0% | 413 | $0.00 |
| 93320 | 0% | 649 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 187 | $0.00 |
| A9270 | Non-covered item or service | 0% | 943 | $0.00 |
| 80050 | General health panel | 0% | 16 | $0.00 |
| 94761 | 0% | 85 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 26 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 32 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 29 | $0.00 |
| 83520 | 0% | 76 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 12 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 199 | $0.00 |
| 94760 | 0% | 12 | $0.00 | |
| 83883 | 0% | 13 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 28 | $0.00 |
| J3490 | Unclassified drugs | 0% | 29 | $0.00 |
| 12001 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.